CN113786409B - 包含磷酸肌醇3-激酶抑制剂和第二抗增殖剂的组合物 - Google Patents

包含磷酸肌醇3-激酶抑制剂和第二抗增殖剂的组合物 Download PDF

Info

Publication number
CN113786409B
CN113786409B CN202111104917.2A CN202111104917A CN113786409B CN 113786409 B CN113786409 B CN 113786409B CN 202111104917 A CN202111104917 A CN 202111104917A CN 113786409 B CN113786409 B CN 113786409B
Authority
CN
China
Prior art keywords
inhibitor
group
kinase inhibitor
alkyl
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202111104917.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN113786409A (zh
Inventor
斯蒂芬·约瑟夫·沙特勒沃斯
安德鲁·大卫·惠尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fukang Shanghai Health Technology Co ltd
Original Assignee
Fukang Shanghai Health Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fukang Shanghai Health Technology Co ltd filed Critical Fukang Shanghai Health Technology Co ltd
Priority to CN202111104917.2A priority Critical patent/CN113786409B/zh
Publication of CN113786409A publication Critical patent/CN113786409A/zh
Application granted granted Critical
Publication of CN113786409B publication Critical patent/CN113786409B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202111104917.2A 2015-08-19 2016-08-19 包含磷酸肌醇3-激酶抑制剂和第二抗增殖剂的组合物 Active CN113786409B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111104917.2A CN113786409B (zh) 2015-08-19 2016-08-19 包含磷酸肌醇3-激酶抑制剂和第二抗增殖剂的组合物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1514760.6 2015-08-19
GBGB1514760.6A GB201514760D0 (en) 2015-08-19 2015-08-19 Compounds and method of use
CN201680057437.6A CN108348505B (zh) 2015-08-19 2016-08-19 包含磷酸肌醇3-激酶抑制剂和第二抗增殖剂的组合物
CN202111104917.2A CN113786409B (zh) 2015-08-19 2016-08-19 包含磷酸肌醇3-激酶抑制剂和第二抗增殖剂的组合物
PCT/GB2016/052575 WO2017029517A1 (en) 2015-08-19 2016-08-19 Compositions comprising phosphoinositide 3-kinase inhibitors and a second antiproliferative agent

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201680057437.6A Division CN108348505B (zh) 2015-08-19 2016-08-19 包含磷酸肌醇3-激酶抑制剂和第二抗增殖剂的组合物

Publications (2)

Publication Number Publication Date
CN113786409A CN113786409A (zh) 2021-12-14
CN113786409B true CN113786409B (zh) 2024-04-02

Family

ID=54258859

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202111104917.2A Active CN113786409B (zh) 2015-08-19 2016-08-19 包含磷酸肌醇3-激酶抑制剂和第二抗增殖剂的组合物
CN201680057437.6A Active CN108348505B (zh) 2015-08-19 2016-08-19 包含磷酸肌醇3-激酶抑制剂和第二抗增殖剂的组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201680057437.6A Active CN108348505B (zh) 2015-08-19 2016-08-19 包含磷酸肌醇3-激酶抑制剂和第二抗增殖剂的组合物

Country Status (22)

Country Link
US (3) US10668077B2 (enExample)
EP (1) EP3337477B1 (enExample)
JP (1) JP2018523689A (enExample)
KR (1) KR20180064387A (enExample)
CN (2) CN113786409B (enExample)
AU (1) AU2016307885B2 (enExample)
CA (1) CA2995898A1 (enExample)
DK (1) DK3337477T3 (enExample)
ES (1) ES2939815T3 (enExample)
FI (1) FI3337477T3 (enExample)
GB (1) GB201514760D0 (enExample)
HR (1) HRP20230376T1 (enExample)
HU (1) HUE061615T2 (enExample)
IL (1) IL257499A (enExample)
LT (1) LT3337477T (enExample)
MX (1) MX2018001926A (enExample)
PL (1) PL3337477T3 (enExample)
PT (1) PT3337477T (enExample)
RS (1) RS64095B1 (enExample)
SI (1) SI3337477T1 (enExample)
SM (1) SMT202300063T1 (enExample)
WO (1) WO2017029517A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9200007B2 (en) 2009-08-20 2015-12-01 Karus Therapeutics Limited Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors
GB201204125D0 (en) 2012-03-08 2012-04-25 Karus Therapeutics Ltd Compounds
GB201402431D0 (en) 2014-02-12 2014-03-26 Karus Therapeutics Ltd Compounds
EP3824908A1 (en) 2015-04-10 2021-05-26 Capsugel Belgium NV Abiraterone acetate lipid formulations
GB201514754D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
GB201514760D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds and method of use
GB201514758D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Formulation
GB201514751D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
WO2020055840A1 (en) * 2018-09-11 2020-03-19 Curis Inc. Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
EP3854397A4 (en) * 2018-09-18 2022-07-13 Kabushiki Kaisha Yakult Honsha COMBINATION OF CANCER THERAPY USING QUINOLINECARBOXAMIDE DERIVATIVE
WO2020174420A1 (en) * 2019-02-27 2020-09-03 Astrazeneca Ab Method of treating a fibrotic disease or condition or of an interstitial lung disease using a src kinase inhibitor
CN111904958B (zh) * 2019-05-09 2022-09-13 浙江大学 Umi-77作为线粒体自噬诱导剂在制备治疗炎症及神经退行性疾病药物中的应用
GB201909468D0 (en) * 2019-07-01 2019-08-14 Karus Therapeutics Ltd Compounds for treating cancer
WO2022105836A1 (en) * 2020-11-19 2022-05-27 Guangzhou Healthquest Pharma Co., Ltd. Combination therapies for treating cancer

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101501035A (zh) * 2006-08-08 2009-08-05 中外制药株式会社 作为p13k抑制剂的嘧啶衍生物及其用途
CN101849934A (zh) * 2010-05-25 2010-10-06 苏州大学 一种磷脂酰肌醇-3-激酶抑制剂及其应用
CN101939006A (zh) * 2007-09-12 2011-01-05 吉宁特有限公司 磷酸肌醇3-激酶抑制剂化合物与化疗剂的联合以及使用方法
CN102498115A (zh) * 2009-08-20 2012-06-13 卡鲁斯治疗有限公司 作为磷酸肌醇3-激酶抑制剂的三环杂环化合物
CN106103450A (zh) * 2014-02-12 2016-11-09 卡鲁斯治疗有限公司 作为磷酸肌醇3‑激酶抑制剂的三环杂环化合物

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1445742A1 (de) 1963-11-06 1968-12-19 Bayer Ag Verfahren zur Herstellung von 2-Stellung substituierten Benzoxazinonen
US4017500A (en) 1973-07-16 1977-04-12 Schering Corporation Certain 8-amino-1,7-naphthyridines
BE786081A (fr) * 1971-07-13 1973-01-10 Uniroyal Sa Appareil et procede pour maintenir les tringles des bourrelets de pneu
US5703075A (en) 1988-12-21 1997-12-30 Pharmacia & Upjohn Company Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
CN1250294A (zh) * 1999-07-27 2000-04-12 邮电部武汉邮电科学研究院 以太网与同步数字体系或同步光网络融合的适配方法
ES2310166T3 (es) 1999-08-03 2009-01-01 Lilly Icos Llc Composicion farmaceutica que contiene tadalafil.
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
ATE503743T1 (de) 2000-04-27 2011-04-15 Astellas Pharma Inc Kondensierte heteroarylderivate
US6635640B2 (en) 2000-06-30 2003-10-21 Sugen, Inc. 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
EP2277867B1 (en) 2002-07-15 2012-12-05 Symphony Evolution, Inc. Compounds, pharmaceutical compositions thereof and their use in treating cancer
FR2846657B1 (fr) 2002-11-05 2004-12-24 Servier Lab Nouveaux composes pyridopyrimidinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP1724267B1 (en) 2004-02-26 2013-11-06 ASKA Pharmaceutical Co., Ltd. Pyrimidine derivative
CA2567883A1 (en) 2004-05-25 2005-12-15 Icos Corporation Methods for treating and/or preventing aberrant proliferation of hematopoietic cells
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
EP2354139A1 (en) 2005-05-20 2011-08-10 Vertex Pharmaceuticals Incorporated Pyrrolopyridines useful as inhibitors of protein kinase
JP2009523812A (ja) 2006-01-19 2009-06-25 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド 融合へテロ二環式キナーゼ阻害剤
KR20090021155A (ko) 2006-04-26 2009-02-27 에프. 호프만-라 로슈 아게 Ｐｉ3ｋ 억제제로서의 피리미딘 유도체
EP2046799B1 (en) 2006-04-26 2017-07-19 Genentech, Inc. Phosphoinositide 3-kinase inhibitor compounds and pharmaceutical compositions containing them
ATE510840T1 (de) 2006-06-26 2011-06-15 Ucb Pharma Sa Kondensierte thiazol-derivate als kinasehemmer
CA2669399A1 (en) 2006-11-13 2008-05-29 Eli Lilly & Co. Thienopyrimidinones for treatment of inflammatory disorders and cancers
US20080312199A1 (en) 2006-12-15 2008-12-18 Glinsky Gennadi V Treatments of therapy resistant diseases and drug combinations for treating the same
CA2677096A1 (en) 2007-01-31 2008-08-07 Vertex Pharmaceuticals Incorporated Kinase inhibitors
EP2139332A4 (en) 2007-03-28 2010-04-21 Merck Sharp & Dohme SUBSTITUTED PYRIDO [2,3-D] PYRIMIDIN DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS
WO2008150827A1 (en) 2007-05-29 2008-12-11 Smithkline Beecham Corporation Naphthyridine, derivatives as p13 kinase inhibitors
GB0710528D0 (en) 2007-06-01 2007-07-11 Glaxo Group Ltd Novel compounds
US20110201608A1 (en) 2008-08-05 2011-08-18 Boehringer Ingelheim International Gmbh Substituted naphthyridines and use thereof as medicines
US20110257170A1 (en) 2008-10-03 2011-10-20 Merck Serono Sa 4-morpholino-pyrido[3,2-d]pyrimidines
GB2465405A (en) 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
WO2011012883A1 (en) 2009-07-29 2011-02-03 Karus Therapeutics Limited Benzo [e] [1, 3 ] oxazin-4-one derivatives as phosphoinositide 3-kinase inhibitors
WO2011079231A1 (en) 2009-12-23 2011-06-30 Gatekeeper Pharmaceutical, Inc. Compounds that modulate egfr activity and methods for treating or preventing conditions therewith
GB201007347D0 (en) 2010-04-30 2010-06-16 Karus Therapeutics Ltd Compounds
EP2518070A1 (en) 2011-04-29 2012-10-31 Almirall, S.A. Pyrrolotriazinone derivatives as PI3K inhibitors
JP5427321B2 (ja) 2011-07-27 2014-02-26 アストラゼネカ アクチボラグ ２−（２，４，５−置換−アニリノ）ピリミジン化合物
WO2013017480A1 (en) 2011-07-29 2013-02-07 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
GB201204125D0 (en) 2012-03-08 2012-04-25 Karus Therapeutics Ltd Compounds
EP2922851B8 (en) 2012-11-20 2017-09-27 F. Hoffmann-La Roche AG Aminopyrimidine compounds as inhibitors of t790m containing egfr mutants
ES2688815T3 (es) 2013-05-10 2018-11-07 Karus Therapeutics Limited Inhibidores de histona desacetilasa novedosos
SG10201709926VA (en) * 2013-05-30 2017-12-28 Infinity Pharmaceuticals Inc Treatment of cancers using pi3 kinase isoform modulators
WO2014210354A1 (en) 2013-06-28 2014-12-31 Genentech, Inc. Azaindazole compounds as inhibitors of t790m containing egfr mutants
ES2929576T3 (es) 2013-10-08 2022-11-30 Acetylon Pharmaceuticals Inc Combinaciones de inhibidores de histona deacetilasa 6 y el inhibidor de Her2 lapatinib para el uso en el tratamiento del cáncer de mama
ES2818933T3 (es) 2013-10-10 2021-04-14 Acetylon Pharmaceuticals Inc Inhibidores de la HDAC en combinación con los inhibidores de la pi3k, para el tratamiento del linfoma no Hodgkin
GB201321738D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
GB201321730D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321729D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321728D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
MA40933A (fr) 2014-11-11 2017-09-19 Piqur Therapeutics Ag Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines
GB201514756D0 (en) * 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compound and method of use
GB201514751D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
GB201514758D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Formulation
GB201514760D0 (en) * 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds and method of use
GB201514754D0 (en) * 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
GB201909468D0 (en) 2019-07-01 2019-08-14 Karus Therapeutics Ltd Compounds for treating cancer

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101501035A (zh) * 2006-08-08 2009-08-05 中外制药株式会社 作为p13k抑制剂的嘧啶衍生物及其用途
CN101939006A (zh) * 2007-09-12 2011-01-05 吉宁特有限公司 磷酸肌醇3-激酶抑制剂化合物与化疗剂的联合以及使用方法
CN102498115A (zh) * 2009-08-20 2012-06-13 卡鲁斯治疗有限公司 作为磷酸肌醇3-激酶抑制剂的三环杂环化合物
CN101849934A (zh) * 2010-05-25 2010-10-06 苏州大学 一种磷脂酰肌醇-3-激酶抑制剂及其应用
CN106103450A (zh) * 2014-02-12 2016-11-09 卡鲁斯治疗有限公司 作为磷酸肌醇3‑激酶抑制剂的三环杂环化合物

Also Published As

Publication number Publication date
CN108348505A (zh) 2018-07-31
US10668077B2 (en) 2020-06-02
IL257499A (en) 2018-07-31
US12257254B2 (en) 2025-03-25
PT3337477T (pt) 2023-03-20
FI3337477T3 (fi) 2023-04-27
US11291669B2 (en) 2022-04-05
EP3337477B1 (en) 2023-02-01
US20180243313A1 (en) 2018-08-30
HK1251467A1 (en) 2019-02-01
DK3337477T3 (en) 2023-02-20
GB201514760D0 (en) 2015-09-30
US20210069200A1 (en) 2021-03-11
EP3337477A1 (en) 2018-06-27
SI3337477T1 (sl) 2023-04-28
MX2018001926A (es) 2018-06-19
CN108348505B (zh) 2021-10-12
CN113786409A (zh) 2021-12-14
CA2995898A1 (en) 2017-02-23
KR20180064387A (ko) 2018-06-14
SMT202300063T1 (it) 2023-03-17
ES2939815T3 (es) 2023-04-27
RS64095B1 (sr) 2023-04-28
HRP20230376T1 (hr) 2023-06-23
AU2016307885B2 (en) 2019-07-25
JP2018523689A (ja) 2018-08-23
LT3337477T (lt) 2023-03-10
PL3337477T3 (pl) 2023-07-03
US20230066999A1 (en) 2023-03-02
HUE061615T2 (hu) 2023-07-28
WO2017029517A1 (en) 2017-02-23
AU2016307885A1 (en) 2018-03-08

Similar Documents

Publication Publication Date Title
CN113786409B (zh) 包含磷酸肌醇3-激酶抑制剂和第二抗增殖剂的组合物
ES2673278T3 (es) Compuestos heterocíclicos tricíclicos como inhibidores de la fosfoinositol 3-cinasa
EP3337484A1 (en) Compositions comprising a pi3k inhibitor and an hdac inhibitor
JP2020514377A (ja) ピリミジニル−ピリジルオキシ−ナフチル化合物及びｉｒｅ１関連疾患及び障害を治療する方法
CA2995902A1 (en) Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors
TW202400589A (zh) 四氫異喹啉異雙功能ｂｃｌ—ｘｌ降解劑
ES2939358T3 (es) Derivados de quinolina útiles como inhibidores de tirosina cinasa
HK40065474A (en) Compositions comprising phosphoinositide 3-kinase inhibitors and a second antiproliferative agent
HK1251467B (en) Compositions comprising phosphoinositide 3-kinase inhibitors and a second antiproliferative agent
HK1227870A1 (en) Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors
HK1227870B (en) Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40065474

Country of ref document: HK

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20220905

Address after: Building 26, Lane 1000, Zhangheng Road, Pudong New Area, Shanghai

Applicant after: Fukang (Shanghai) Health Technology Co.,Ltd.

Address before: Oxfordshire

Applicant before: KARUS THERAPEUTICS Ltd.

GR01 Patent grant
GR01 Patent grant